Skip to main content

IL-17

Dr. J. Giles reviews adipose tissue as a source of inflammatory cytokines like TNF, IL-6, IL-1, IL17, etc. #RWCS24 @RWCSmtg @RheumNow https://t.co/AYD9PpwNE6
Dr. Rachel Tate @uptoTate( View Tweet )
Feb 16, 2024

Co-management of Psoriatic Disease

It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. In an ideal world this would involve a combined clinic with our local friendly dermatologist. For many of us, however, this is not practical for many reasons. The excellent Saturday morning

Read Article

Pre-Treatment Testing with Biologics Falls Short

Feb 01, 2024

US commercial insurance claim analysis of laboratory screening and monitoring practices in chronic inflammatory skin disease (CISD) patients shows that < 60% received the recommended pretreatment testing when starting systemic immunomodulatory treatment.

Read Article
#RNL2024 @RheumNow @_AprilArmstrong Bimekizumab: IL-17A and IL-17F dual efficacy, unlike the prior IL-17i drugs - Fast onset - High efficacy with 2/3 PASI 100 by wk 16 (BE READY) https://t.co/cKh7j4KBs9
Eric Dein @ericdeinmd( View Tweet )
Jan 27, 2024
IL-17 pathway as a target in giant cell arteritis - full read review of pathogenic role of IL-17 and Th17 cells, in #GCA; backed up by the phase II proof-of-principle TiTAIN study showing potential efficacy of secukinumab in GCA pts https://t.co/MThzw2joGO https://t.co/PmrJjf9C3a
Dr. John Cush @RheumNow( View Tweet )
Jan 21, 2024

Methotrexate Nodulosis (1.19.2024)

Jan 19, 2024

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. How good (or not) are rheumatologists and what to do about MTX nodulosis?




  1. Network meta-analyses of 153 trials & 8713 patients w/ chronic pain from TMJ disorders; Most effective (pain

Read Article

2023 Rheumatology Year in Review

Jan 12, 2024

Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.  



2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.  



Below is

Read Article

2023 Rheumatology Year in Review

Jan 10, 2024

Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.

Read Article
Anti-TNF mAbs, JAKi & anti-IL17 Rx appear protective against anterior Uveitis in AxSpA pts. Network Metanalysis of 44 trials, AU IR -TNF mAb: 4.1, ETN: 5.4, IL17i: 2.8, JAKi: 1.5, & placebo: 10.8. AU risk: TNFi < JAKi < IL-17i < ETN << PBO https://t.co/3zIcvuIaBV https://t.co/UseZ6t00EB
Dr. John Cush @RheumNow( View Tweet )
Jan 07, 2024

Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis

Jan 04, 2024

An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).

Read Article

Best of 2023: Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

Dec 29, 2023

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Read Article

ICYMI: Bimekizumab is Coming…in Third Place

Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and

Read Article
UK Dermatology Registry of 13 699 Psoriasis pts on biologics (25K biologic exposures) found 1% risk of paradoxical eczema. Biologics included inhibitors of TNF, IL-17, IL12/23, IL-23. Lowest risk w/ IL-23i (0.56/100kPY), and higher w/ IL-17i (1.22) https://t.co/fOX6VGJQLk https://t.co/u1p1sidCte
Dr. John Cush @RheumNow( View Tweet )
Dec 10, 2023
Greigert et al. IL17 in GCA. Increases vascular inflammation. Synergistic effect on myofibroblasts with IFN-γ - increases IL-1B, IL-6, GM-CSF, CCL20 (recruits T cells), CCL2 (recruits monocytes), VEGF (neoangiogenic). Abstr#2599 #ACR23 @RheumNow https://t.co/p4GumZStAZ https://t.co/zZv0TF4fmn
Richard Conway ( View Tweet )
Nov 15, 2023
Anterior uveitis incidence across different axSpA treatments Large review and meta-analysis on TNFi, IL-17i, JAKi Immunomodulatory therapy protective against uveitis flare Greatest in TNFi and JAKi @RheumNow #ACR23 Abs# 2550 https://t.co/l3BTL3GuRt
Robert B Chao, MD ( View Tweet )
Nov 14, 2023
Persistence of IL-17i vs. TNFi in PsA treatment Large database study Persistence of IL-17i slightly greater than TNFi over 12 months Are IL-17i a better longterm strategy for PsA pts? @RheumNow #ACR23 Abs# 2240 https://t.co/9km5XgXcLE
Robert B Chao, MD ( View Tweet )
Nov 14, 2023
A#2545 IV SEC for SpA #ACR23 @Rheumow Approved by FDA, though diff dose Who: Medicare/cost/QoL benefit for IV or obese (wt based dose) W16: 41% ASAS40 v 23% PBO W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%) SAE 6%, discontinuation 3.5% #ACRBest https://t.co/ruW0ys49gk
Eric Dein ( View Tweet )
Nov 14, 2023
Very cool meta analysis of IL17i RCTs in PsA No change in MACE in DMARD naieve pts initiating IL17i across RCTs A skosh underpowered but worthwhile question & useful data @RheumNow #ACR23 Abstr2254 https://t.co/ZN8QYgSA1A
Mike Putman @EBRheum( View Tweet )
Nov 14, 2023
Another day, another bimekizumab (IL17i) study Across 2 trials, improved PsA specific QOL ("PsAID") metrics Nice to see focus on PROs & I always love a good spidergram @RheumNow #ACR23 Absr2249 https://t.co/dsLXstPzt2
Mike Putman @EBRheum( View Tweet )
Nov 14, 2023
Later today at #ACR23 at 4pm See Ab#2545 on IV secukinumab for AxSpA Read about it now on @RheumNow: https://t.co/s9IinpVxgR

Eric Dein ( View Tweet )

Nov 14, 2023

IV Secukinumab for AxSpa

Nov 14, 2023

The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. Data for this new approval will be presented at ACR Convergence on November 14th by Dr. Atul Deodhar.

Read Article
TNF AND IL17 was equally effective in Axial SpA! #ACR23 #Reviewcourse https://t.co/oofQkvsJ3f
Nouf Al hemmadi ( View Tweet )
Nov 12, 2023
#ACR23 IV secukinumab vs placebo at 52 Weeks @RheumNow https://t.co/4zQa37tN4l
Dellal ( View Tweet )
Nov 12, 2023
Phase 3 Study of IV Secukinumab for treatment of PsA - efficacious and safety profile similar to Subq version ~60% ACR 50 response maintained at week 52 2nd responses of MDA, PASI90, enthesitis, dactylitis resolution met @RheumNow #ACR23 Abs#0776 https://t.co/jikWd4fnGm
Robert B Chao, MD ( View Tweet )
Nov 12, 2023
Long term safety data for bimekizumab (IL17i) in Psa & axSpA Overall as expected; increased infections (esp fungal/candida) & hepatic events No new signals... uveitis flares is interesting Need H2H of IL17's! IXE vs SEC vs BIM @RheumNow #ACR23 Abstr 0511 https://t.co/pBqly2JylA
Mike Putman @EBRheum( View Tweet )
Nov 12, 2023